April 6, 2021
Daiichi Sankyo aims to generate group sales of 1.6 trillion yen and 600 billion yen in oncology revenue in the year ending March 2026 by maximizing the potential of its three lead antibody-drug conjugate (ADC) assets, according to its new...read more